ArticleInternational cancer conference journal2025
Chronic progressive pulmonary aspergillosis within the irradiated field after stereotactic body radiotherapy: two case reports.
Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiation therapy (SBRT) is the standard treatment for patients who are medically inoperable or who refuse surgery with stage I non-small cell lung cancer (NSCLC). While acute lymphopenia following SBRT is documented, the long-term effects on the immune system and infectious disease remain unclear. In this report, we present two cases of chronic progressive pulmonary aspergillosis (CPPA) occurring within the irradiated field following SBRT for inoperable stage I NSCLC. Case 1 was a man in his 70 s with a history of smoking and a previous pulmonary resection and SBRT for metachronous primary lung cancer. He received SBRT for T1aN0M0 NSCLC in the right lower lobe as his third primary lung cancer. After 20 months, the patient developed a cough and sputum, and a computed tomography (CT) scan revealed a cavity shadow in the irradiated field, which led to the diagnosis of CPPA. Intravenous voriconazole was immediately started, and after 3 week's administration, the symptoms improved, and the cavity disappeared. After 34 months, the patient died with no recurrence of CPPA and lung cancer. Case 2 was a man in his 80 s with a history of smoking and previous pulmonary resection for lung cancer. He received SBRT for T1cN0M0 NSCLC in the right lower lobe as his second primary lung cancer. After 19 months, the patient developed a fever, and a CT scan revealed a cavity shadow in the irradiated field, which led to the diagnosis of CPPA. Oral itraconazole was administered, followed by diarrhea and anorexia. After 22 days, the patient died. During the follow-up period, there was no recurrence of lung cancer. Risk factors for CPPA include a history of smoking and lung resection, common among candidates for pulmonary SBRT. When a cavity shadow develops following SBRT, differentiating consolidation as radiation pneumonitis, local recurrence, or infection can be challenging. When a cavity is identified on a follow-up CT scan after SBRT, it is crucial to include CPPA in the differential diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.